2020
AstraZeneca sold the rights on Atakand of Cheplapharm Arzneimittel company
At the end of October, 2020 AstraZeneca sold the commercial rights to the two medicines of the German pharmaceutical company Cheplapharm Arzneimittel. Business on production of the cardiovascular medicines "Atakand" and "Atakand Plus" was given for $400 million Read more here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |